Phenelzine

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Retrieved on: 
목요일, 12월 7, 2023

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.
  • Carbidopa/levodopa (CD/LD), which works to control the symptoms of PD, has been the gold-standard treatment for PD since the 1970s.
  • ONGENTYS® works by inhibiting the COMT enzyme – which breaks down LD – making more LD available to reach the brain, thereby reducing “Off” time.
  • The financial terms of the agreement were not disclosed, and any incremental expenses associated with this product are contemplated within Amneal’s guidance.

Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”

Retrieved on: 
수요일, 8월 2, 2023

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign.
  • INBRIJA is not to be used by people who have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine, within the last 2 weeks.
  • I’m determined to make every day, every moment, count, and to live a full life with my family and friends.
  • The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Watch out for dangerous combinations of over-the-counter cold medicine and prescription drugs – two pharmacoepidemiology experts explain the risks

Retrieved on: 
금요일, 4월 21, 2023

When colds, flus and allergies hit, many people automatically turn to over-the-counter medications to push through and treat their symptoms.

Key Points: 
  • When colds, flus and allergies hit, many people automatically turn to over-the-counter medications to push through and treat their symptoms.
  • Nearly 70% of adults in the U.S. use over-the-counter medications as a first-line response for treating cold and flu symptoms.
  • We are a pharmacoepidemiologist and pharmacist team and we investigate adherence to medications and potential harms of medications associated with drug-drug interactions.
  • Another study estimated that every year, 26,735 people went to the emergency room for adverse events related to over-the-counter cold and cough medications.

The dangers of mixing medications

    • Pharmacists and physicians are typically knowledgeable about potential drug interactions, so it is very important for patients to ask their health care providers which over-the-counter medications are safe for them to use.
    • It is important to read the package ingredients of over-the-counter medications closely to avoid duplication of doses.
    • Cold medications are typically made up of multiple ingredients, including pain relievers, nasal decongestants and cough suppressants or expectorants.
    • Combining these decongestants with monoaminooxidase inhibitors or tricyclic antidepressants could lead to very high blood pressure and heart rhythm problems.

Each person responds to drugs differently

    • As we age, our bodies begin to lose the ability to efficiently clear drugs, which increases the risk of adverse events and unintentional overdoses.
    • Some drugs can be dangerous for people who have particular health conditions.
    • In addition, since these drugs are associated with increased blood pressure, patients with hypertension, hyperthyroidism or heart disease should be careful when using them, or avoid them altogether.

Alternatives for children

    • The Food and Drug Administration and the Centers for Disease Control and Prevention do not recommend giving cold medications to children under age 4.
    • Because of a variety of factors, young children have a higher risk of accidental overdose and adverse events that could lead to death.
    • Research has shown that honey can be helpful for reducing cold and flu symptoms in children older than age 1.

Pregnancy best practices

    • Acetaminophen is the doctor-recommended over-the-counter medication for management of pain and fever at any stage of pregnancy.
    • Any other pain relievers or anti-inflammatory medicine such as ibuprofen, ketoprofen, naproxen and aspirin should not be taken during pregnancy without a doctor’s approval.
    • For symptoms such as nasal congestion during pregnancy, a decongestant called oxymetazoline in its intranasal form is the drug of choice.

Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash

Retrieved on: 
월요일, 12월 5, 2022

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible Senior Secured Notes Indenture.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible Senior Secured Notes Indenture.
  • Acorda may elect to make interest payments under the Indenture in cash or shares of the Companys common stock.
  • The Company made the interest payment using cash that was placed in escrow when the Notes were issued, which is reported on the Companys balance sheet as restricted cash.
  • By making this interest payment in cash, the Company has ensured that there was no dilution to shareholders.

Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders

Retrieved on: 
금요일, 11월 11, 2022

Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the Companys stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the Companys stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders.
  • We are grateful to our shareholders who supported this proposal at a ratio of almost two and a half to one.
  • Authorizing our board to implement a reverse stock split is an important tool, if needed, to ensure that we do not become delisted by Nasdaq, said Ron Cohen, M.D., President and CEO of Acorda Therapeutics.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders

Retrieved on: 
금요일, 11월 4, 2022

Acorda Therapeutics, Inc. (Nasdaq: ACOR ) convened its Special Meeting of Stockholders on November 4, 2022, and a proposal to adjourn the meeting was approved in order to provide stockholders with additional time to vote on Proposal Two, Reverse Stock Split.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR ) convened its Special Meeting of Stockholders on November 4, 2022, and a proposal to adjourn the meeting was approved in order to provide stockholders with additional time to vote on Proposal Two, Reverse Stock Split.
  • The sole matter of business before the reconvened Special Meeting will be to approve Proposal Two, the Reverse Stock Split.
  • Proposal Three, allowing the Special Meeting to be adjourned, was approved at the Special Meeting.
  • The record date for determining stockholders eligible to vote on Proposal Two at the reconvened Special Meeting remains September 9, 2022.

Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance

Retrieved on: 
목요일, 10월 27, 2022

Acorda will hold a video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET / 10:00am PT.

Key Points: 
  • Acorda will hold a video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET / 10:00am PT.
  • The call will review Acordas long-term business plan and the items on the ballot for Acordas Special Meeting of Shareholders on November 4, 2022.
  • Stockholders are encouraged to cast your vote promptly FOR the Reverse Split proposal without further delay.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022

Retrieved on: 
화요일, 10월 25, 2022

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its third quarter 2022 update and financial results on Tuesday, November 1 at 4:30 p.m.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its third quarter 2022 update and financial results on Tuesday, November 1 at 4:30 p.m.
  • After you have registered, you will receive a confirmation email with the Webcast details.
  • On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join.
  • The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com .

Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.

Retrieved on: 
금요일, 10월 21, 2022

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET, 10:00am PT.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET, 10:00am PT.
  • The call will review the items on the ballot for Acordas Special Meeting of Shareholders on November 4, 2022.
  • To participate in the video event:
    Click the link below from a laptop or mobile device.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split

Retrieved on: 
수요일, 10월 19, 2022

We appreciate the confirmation of the need for and urgency of this proposal, said John P. Kelley, Chair of Acordas Board of Directors.

Key Points: 
  • We appreciate the confirmation of the need for and urgency of this proposal, said John P. Kelley, Chair of Acordas Board of Directors.
  • The proposal to allow the board to implement a reverse split, if necessary, is critical to ensure that Acorda does not become delisted from Nasdaq.
  • If delisting were to occur, we may be in default on our agreements with our debtholders, and may need to declare bankruptcy.
  • Stockholders are encouraged to cast your vote promptly FOR the Reverse Split proposal without further delay.